Estrogen receptor signaling drives immune evasion and immunotherapy resistance in HR+ breast cancer
Journal of Clinical Investigation · 16.01.2026 · 136 (2)
DOI: 10.1172/jci193153 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 25.11.2025. Verfasst von José Ángel Palomeque und 22 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research Program, Hospital del Mar Research Institute (HMRI), Barcelona, Spain. Hauptthemen laut MEDLINE: Breast Neoplasms, Estrogen Receptor alpha, Signal Transduction, Immunotherapy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, Fundación Científica Asociación Española Contra el Cáncer.
Abstract (Originalsprache)
Hormone receptor–positive (HR + ) breast cancers (BCs) are typically “immune-cold,” poorly immune-infiltrated tumors that do not respond to immune-checkpoint blockade (ICB) therapies. Using clinical data, we report that estrogen receptor α (ERα) signaling was associated with immunosuppressive pathways and a lack of response to ICB in patients with HR + BC. In this study, we validated ER-mediated immunosuppression by engineering and modulating the ER in preclinical models in vitro, in vivo, and ex vivo. Mechanistically, we found that ERα hijacked LCOR, a nuclear receptor corepressor, thereby preventing LCOR’s function in the induction of tumor immunogenicity and immune infiltration, which is normally observed in the absence of ERα, such as in ER – BC. In HR + BC, we demonstrate that the molecular disruption of LCOR and ERα interaction using anti-ER therapies or using a mutant of the LCOR nuclear receptor–binding domain (LSKLL into LSKAA) that does not interact with ERα, restored the immunogenic functions of LCOR. Remarkably, the LCOR-ERα disruption converted HR + BC immune-cold tumors into immune-hot tumors responsive to ICB by increased antigen presentation machinery expression, immune infiltration, T cell recognition, and T cell–mediated killing. In conclusion, ERα inhibition and the disruption of LCOR-ERα interaction represent a therapeutic strategy and an opportunity to elicit immunotherapeutic benefit in patients with HR + BC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Research Program, Hospital del Mar Research Institute (HMRI), Barcelona, Spain.
- Pathology Department, Hospital del Mar, Barcelona, Spain.
- Medical Oncology Department, Hospital del Mar, Barcelona, Spain.
- Universitat Pompeu Fabra, Barcelona, Spain.
- Centro de Investigación Biomédica en Red de Oncología (CIBERONC-ISCIII), Madrid, Spain.
- Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA.
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- Fundación Científica Asociación Española Contra el Cáncer
Zitieren
APA
Palomeque, J. Á., Serra-Mir, G., Blasco-Benito, S., Brunel, H., Torren-Duran, P., Pérez-Núñez, I., Cannatá, C., Comerma, L., Menendez, S., Servitja, S., Martos, T., Castro, M., Borges, R. L., López-Velazco, J. I., Manzano, S., Duro-Sánchez, S., Arribas, J., Caffarel, M. M., Urruticoechea, A., …, & Celià-Terrassa, T. (2026). Estrogen receptor signaling drives immune evasion and immunotherapy resistance in HR+ breast cancer. Journal of Clinical Investigation, 136(2). https://doi.org/10.1172/jci193153
Vancouver
Palomeque JÁ, Serra-Mir G, Blasco-Benito S, Brunel H, Torren-Duran P, Pérez-Núñez I, et al. Estrogen receptor signaling drives immune evasion and immunotherapy resistance in HR+ breast cancer. Journal of Clinical Investigation. 2026;136(2). doi:10.1172/jci193153
BibTeX
@article{Palomeque2026,
author = {Palomeque, José Ángel and Serra-Mir, Gabriel and Blasco-Benito, Sandra and Brunel, Helena and Torren-Duran, Pau and Pérez-Núñez, Iván and Cannatá, Chiara and Comerma, Laura and Menendez, Silvia and Servitja, Sonia and Martos, Tamara and Castro, Maria and Borges, Rodrigo L and López-Velazco, Joanna I and Manzano, Sara and Duro-Sánchez, Santiago and Arribas, Joaquín and Caffarel, María M and Urruticoechea, Ander and Seoane, José A and Morey, Lluis and Albanell, Joan and Celià-Terrassa, Toni},
title = {Estrogen receptor signaling drives immune evasion and immunotherapy resistance in HR+ breast cancer},
journal = {Journal of Clinical Investigation},
year = {2026},
volume = {136},
number = {2},
doi = {10.1172/jci193153}
}
EUVIMED